Effects of comorbid and demographic factors on dialysis modality choice and related patient survival in Europe
Moniek W.M. van de Luijtgaarden(Amsterdam UMC Location University of Amsterdam), Kitty J. Jager(Amsterdam University Medical Centers), Christoph Wanner(Universitätsklinikum Würzburg), T. Leivestad, Vianda S Stel(Amsterdam UMC Location University of Amsterdam), F. Jarraya(University of Sfax), Marlies Noordzij(University of Amsterdam), Pietro Ravani(University of Calgary), Staffan Schön, H Puttinger(Medical University of Vienna), Frédéric Collart(French Community of Belgium)
Cited by 117
Related Papers
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
|Kidney International|2019|886
An introduction to inverse probability of treatment weighting in observational research
|Clinical Kidney Journal|2021|877